Hemostemix 
HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。